Parkinson's disease (PD) is a synucleinopathy whose motor syndrome is caused by progressive and selective degeneration of midbrain dopamine (mDA) neurons. PD is the most frequent movement disorder, affecting 1-2% of the population over the age of 65. With our aging population, it is anticipated that the burden on our health care system will escalate. Currently, there are no treatments that can halt or slow down the progression of Parkinson's disease. Because the loss of a specific cell type (i.e., A9 mDA neurons in the substantia nigra) is the main cause of motor PD, it is one of most promising target diseases for cell-based therapy. Indeed, numerous clinical and preclinical studies demonstrated the proof-of-principle that cell transplantation is a viable therapeutic regimen for PD treatment once a limitless, functional, and safe cell source can be established. Among various potential cell sources, we speculate that patient-derived induced pluripotent stem cells (iPSCs) represent the most promising cell source and may lead to personalized cell therapy without immune rejection and ethical issues such as embryo destruction. In support of this, during the last funding cycle, we have made significant progress such as the establishment of mechanism-based novel reprogramming strategies that efficiently generate high quality iPSCs, identification and purification of authentic mDA progenitors, chemical methods to eliminate remaining undifferentiated cells, and novel and efficient differentiation methods. Based on these promising data, we propose to further establish generation of clinical grade iPSCs from sporadic PD fibroblasts, including their characterization, their in vitro differentiation, and the purificaton of mDA progenitors. Furthermore, we will analyze and compare in vivo functional outcomes of mDA progenitors derived from human ESCs and iPSCs using both rodent and primate models of PD. Biological and behavioral outcomes of these transplantation studies will be systematically investigated in a long-term scale. Our proposal will address practical and major issues of patient-specific cell therapy by comparing the functional efficacies of hESC- and hiPSC-derived mDA cells both in vitro and in vivo and will provide invaluable insights and stepping-stones, eventually leading to a new generation of cell replacement therapy for PD.

Public Health Relevance

The 'induced pluripotent stem cell (iPSC)' technology is a promising method that can revolutionize customized cell-based therapies of intractable human diseases such as PD. To realize the potential of using iPSCs in personalized cell-based therapy for PD, we propose to establish and characterize clinically viable iPSC lines by our novel reprogramming methods, to optimize their differentiation and purification of midbrain dopamine cells, and to test their functionality in rodent and primate models. This proposal will provide important stepping-stones for realistic development of a personalized cell-based therapy of PD and will lead to a new generation of cell replacement therapy of PD.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
5R01NS070577-09
Application #
9693331
Study Section
Clinical Neuroplasticity and Neurotransmitters Study Section (CNNT)
Program Officer
Lavaute, Timothy M
Project Start
2010-06-01
Project End
2021-04-30
Budget Start
2019-05-01
Budget End
2020-04-30
Support Year
9
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Mclean Hospital
Department
Type
DUNS #
046514535
City
Belmont
State
MA
Country
United States
Zip Code
Sonntag, Kai-C; Song, Bin; Lee, Nayeon et al. (2018) Pluripotent stem cell-based therapy for Parkinson's disease: Current status and future prospects. Prog Neurobiol 168:1-20
Kim, Kwang-Soo (2017) Toward neuroprotective treatments of Parkinson's disease. Proc Natl Acad Sci U S A 114:3795-3797
Chumarina, Margarita; Azevedo, Carla; Bigarreau, Julie et al. (2017) Derivation of mouse embryonic stem cell lines from tyrosine hydroxylase reporter mice crossed with a human SNCA transgenic mouse model of Parkinson's disease. Stem Cell Res 19:17-20
Cha, Young; Han, Min-Joon; Cha, Hyuk-Jin et al. (2017) Metabolic control of primed human pluripotent stem cell fate and function by the miR-200c-SIRT2 axis. Nat Cell Biol 19:445-456
Brundin, Patrik; Dave, Kuldip D; Kordower, Jeffrey H (2017) Therapeutic approaches to target alpha-synuclein pathology. Exp Neurol 298:225-235
Moon, Jisook; Schwarz, Sigrid C; Lee, Hyun-Seob et al. (2017) Preclinical Analysis of Fetal Human Mesencephalic Neural Progenitor Cell Lines: Characterization and Safety In Vitro and In Vivo. Stem Cells Transl Med 6:576-588
Kim, Woori; Noh, Haneul; Lee, Yenarae et al. (2016) MiR-126 Regulates Growth Factor Activities and Vulnerability to Toxic Insult in Neurons. Mol Neurobiol 53:95-108
Brundin, Patrik; Ma, Jiyan; Kordower, Jeffrey H (2016) How strong is the evidence that Parkinson's disease is a prion disorder? Curr Opin Neurol 29:459-66
Ahn, Sandra; Kim, Tae-Gon; Kim, Kwang-Soo et al. (2016) Differentiation of human pluripotent stem cells into Medial Ganglionic Eminence vs. Caudal Ganglionic Eminence cells. Methods 101:103-12
Kordower, Jeffrey H; Olanow, C Warren (2016) Fetal grafts for Parkinson's disease: Decades in the making. Proc Natl Acad Sci U S A 113:6332-4

Showing the most recent 10 out of 28 publications